Polpharma
↗Starogard Gdański, Poland
Polpharma is the largest Polish pharmaceutical manufacturer and a leading player in the Central and Eastern European (CEE), Caucasus, and Central Asian markets. Founded in 1935, the company specializes in the production of prescription drugs, over-the-counter (OTC) products, and active pharmaceutical ingredients (APIs).
The company operates through a network of five manufacturing plants and three research and development centers. Polpharma is also a significant provider of contract development and manufacturing organization (CDMO) services, offering high-quality dossiers and customized support to international partners. The group is privately owned by Polish investors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$1B-$1.5B
Founded:1935
Ownership:private
Status:operating
FUNDING
Total Raised:$50.3M
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Biosimilars, Injectables
Active Trials:2
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Polpharma Biologics, Farmaprojects
Key Partnerships:Sandoz, Teva, Takeda
COMPETITION
Position:Leader
Competitors:Anthem Biosciences, Patheon, KBI Biopharma
LEADERSHIP
Key Executives:
Sebastian Szymanek - CEO
Robert Knerr - Member of the Management Board
Board Members:Markus Sieger
LINKS
Website:polpharma.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Polpharma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Polpharma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.